Kite, Sangamo form $3bn cancer cell therapy collaboration
Sangamo’s platform will be used to develop next-generation ex vivo cell therapies in oncology. Under the worldwide collaboration, Kite will get exclusive rights to use the ZFN technology to modify
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.